Xeris Biopharma
Biopharmaceutical company developing and commercializing ready-to-use injectable and infusible drug formulations using proprietary XeriSol and XeriJect technologies. Publicly traded on NASDAQ (XERS).
Website
https://www.xerispharma.comLocation
Chicago, Illinois, USA
Founded
2005
Investors
1
Categories
biopharmaceuticals, drug-delivery, biotech, diabetes, public-company
Notes
Xeris Biopharma is a biopharmaceutical company focused on developing and commercializing ready-to-use injectable and infusible drug formulations. The company is publicly traded on NASDAQ under the ticker symbol XERS and is headquartered in Chicago, Illinois.
The company's proprietary technologies include:
- XeriSol: Enables room-temperature stable, ready-to-use liquid formulations of peptides and small molecules
- XeriJect: Enables subcutaneous delivery of large-volume formulations
Xeris has commercialized products for diabetes (Gvoke for severe hypoglycemia) and has a pipeline of products leveraging its formulation technologies.
Team
- Paul R. Edick - Chief Executive Officer
- LinkedIn: linkedin.com/in/pauledick
- Barry M. Deutsch - Chief Financial Officer
Additional Research Findings
- NASDAQ: XERS (publicly traded)
- Part of OMX Ventures portfolio
- XeriSol and XeriJect proprietary technologies
- Gvoke (glucagon) commercialized product
- Diabetes and endocrinology focus
- Chicago, Illinois headquarters
- Founded in 2005
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| OMX Ventures | San Francisco, California, USA | biotech-focused | seedseries-a | 23 |